Mallinckrodt Completes Sale of its Nuclear Imaging Business to IBA Molecular for $690 million
Mallinckrodt plc, a leading specialty pharmaceutical company, announced that it has closed the sale of its global Nuclear Imaging business to IBA Molecular (IBAM) for approximately $690…
Read More...
Read More...